NasdaqGS:APLSBiotechs
How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors
In recent days, Apellis Pharmaceuticals reported strong momentum for its complement inhibitor Empaveli, including preliminary Q4 2025 U.S. net product revenue of about US$35.00 million, reflecting year-over-year growth and rapid uptake in treating paroxysmal nocturnal hemoglobinuria and other rare conditions with high unmet medical needs.
Investor attention has also been drawn to analyst commentary highlighting Empaveli’s early market penetration and underappreciated commercial potential...